Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)

Quality not just a measure, a way of life that drives innovation: Renewable Energy Minister Joshi

The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders

Alankit to undertake pending e-KYC verification for AB PMJAY in Gujarat

Alankit will undertake the verification of pending e-KYC enrollments through the Beneficiary Identification System (BIS) platform provided by the National Health Authority (NHA).

Merck closes license agreement for LM-299

Merck will record a pre-tax charge relating to the upfront payment of $588 million

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination

For people with relapsed or refractory diffuse large B-cell lymphoma

Calquence granted priority review in US for patients with untreated mantle cell lymphoma

Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy

MGC inks agreement to revolutionize allergy care

DFC commits US $20 mn loan to Panacea Biotec towards capacity expansion for hexavalent vaccine

The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines